HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAL 30072

a siderophore with antibacterial activity; structure in first source

Also Known As:

BAL-30072; BAL30072

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Church, Rachel J: 1 article (11/2017)
2.	Engelhardt, Marc: 1 article (11/2017)
3.	Howell, Brett A: 1 article (11/2017)
4.	Krähenbühl, Stephan: 1 article (11/2017)
5.	Maurer, Martina: 1 article (11/2017)
6.	Messner, Simon: 1 article (11/2017)
7.	Paech, Franziska: 1 article (11/2017)
8.	Schmitt-Hoffmann, Anne-Hortense: 1 article (11/2017)
9.	Spickermann, Jochen: 1 article (11/2017)
10.	Wind, Mathias: 1 article (11/2017)

Related Diseases

1.	Urinary Tract Infections (Urinary Tract Infection) 01/01/2016 - "This annex study to a phase 1 study aimed to correlate urinary concentrations and bactericidal titers (UBTs) of BAL30072, a novel siderophore monosulfactam, in healthy subjects in order to evaluate which dosage of BAL30072 should be investigated in a clinical study on complicated urinary tract infection (UTI). "
2.	Infections 10/01/2013 - "The in vitro data suggest that BAL30072 has a potential role in the treatment of infections due to Gram-negative pathogens, including those with important resistances to other agents. " 04/01/2011 - "These data support the continued evaluation of BAL30072 for use in the treatment of infections caused by MDR A. " 10/01/2013 - "In addition, BAL30072 shows powerful synergistic activity in combination with meropenem, potentially expanding its coverage for the treatment of infections caused by problematic species." 11/01/2017 - "BAL30072 is a new monocyclic β-lactam antibiotic under development which provides a therapeutic option for the treatment of severe infections caused by multi-drug-resistant Gram-negative bacteria. "
3.	Cystic Fibrosis (Mucoviscidosis) 02/01/2010 - "cepacia complex isolates from cystic fibrosis (CF) were susceptible to BAL30072 at 1 mg/L and 78% at 8 mg/L, compared with only 22% susceptible to aztreonam at 8 mg/L. "
4.	Burns 10/01/2013 - "baumannii strains producing class D oxacillinases, BAL30072 MICs were all ≤4 mg/L with the exception of the isolate belonging to the UK 'Burn' lineage. "

Related Drugs and Biologics

1.	Siderophores
2.	Lactams
3.	Aztreonam
4.	Anti-Bacterial Agents (Antibiotics)
5.	Meropenem (Merrem)